91 related articles for article (PubMed ID: 178234)
1. Immunotherapy of malignancies: current status.
Eilber FR; Holmes EC; Morton DL; Ramming KP; Sparks FC
AJR Am J Roentgenol; 1976 May; 126(5):1088-93. PubMed ID: 178234
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
3. Nonspecific immunotherapy of malignant tumors.
Milas L; Withers HR
Radiology; 1976 Jan; 118(1):211-8. PubMed ID: 1105663
[TBL] [Abstract][Full Text] [Related]
4. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy.
Richman SP; Gutterman JU; Hersh EM
Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
[TBL] [Abstract][Full Text] [Related]
6. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of sarcomas.
Leventhal BG
Natl Cancer Inst Monogr; 1981 Apr; (56):183-7. PubMed ID: 6170891
[TBL] [Abstract][Full Text] [Related]
8. Effects of BCG and C. parvum treatment on human melanoma xenografts.
Garrett AJ; Reeson DE; Osborn TW; Boulger LR
Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
[TBL] [Abstract][Full Text] [Related]
9. Inconsistent response of B16 melanoma to BCG immunotherapy.
Kreider JW; Bartlett GL; Purnell DM
J Natl Cancer Inst; 1976 Apr; 56(4):803-10. PubMed ID: 1255799
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of malignancy in humans. Current status.
Holmes EC; Eilber FR; Morton DL
JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
[TBL] [Abstract][Full Text] [Related]
11. [Possibilities of immunotherapy in malignant melanoma].
Lewis MG
Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy.
Goodnight JE; Morton DL
Int Adv Surg Oncol; 1978; 1():53-83. PubMed ID: 399764
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in malignant melanomaa.
Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma. Results of treatment employing adjuvant immunotherapy.
Eilber FR; Townsend C; Morton DL
Clin Orthop Relat Res; 1975 Sep; (111):94-100. PubMed ID: 1057467
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
16. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
18. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
